 potent antagonist leukotriene bronchoconstriction human novel leukotriene receptor antagonist ability bronchoconstriction healthy volunteers asthmatic subjects double-blind placebo-controlled crossover study design challenges constant infusion placebo active compound provocative concentration decrease SGaw SGaw mean SEM healthy volunteers asthmatic subjects placebo treatment Intravenous mg bronchoconstriction healthy volunteers inhaled concentration asthmatic subjects mg significant rightward shift dose-response curve mg dose-response curve right potent antagonist bronchoconstriction normal volunteers asthmatic patients small significant increase baseline airway caliber asthmatic patients presence asthmatic airways support role sulfidopeptide leukotrienes pathogenesis asthma